| scholarly article | Q13442814 |
| P50 | author | Andrew I Bell | Q37376473 |
| Martin Rowe | Q37376494 | ||
| Christopher P Fox | Q57040255 | ||
| Wing C Chan | Q87934470 | ||
| Catherine M Bollard | Q91774704 | ||
| Claire Shannon Lowe | Q95607355 | ||
| P2093 | author name string | Alan B Rickinson | |
| Heather M Long | |||
| Steven P Lee | |||
| Javeed Iqbal | |||
| Graham S Taylor | |||
| Simon O'Connor | |||
| Tracey A Haigh | |||
| P2860 | cites work | The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease | Q31088065 |
| Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project | Q33382121 | ||
| The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation | Q33396983 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| Clinical and virologic characteristics of chronic active Epstein-Barr virus infection | Q34082763 | ||
| The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter | Q34355226 | ||
| Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity | Q35634286 | ||
| The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat | Q35842451 | ||
| Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction | Q35868359 | ||
| Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer | Q36059593 | ||
| A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome | Q36344649 | ||
| Two related Epstein-Barr virus membrane proteins are encoded by separate genes | Q36780955 | ||
| Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. | Q39700355 | ||
| Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition | Q39886068 | ||
| Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells | Q39946166 | ||
| Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells | Q40017285 | ||
| EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. | Q40022307 | ||
| Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes | Q40048949 | ||
| Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. | Q40225147 | ||
| Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. | Q40316208 | ||
| Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies | Q40623874 | ||
| Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus | Q40831332 | ||
| Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells | Q42010316 | ||
| Retroviral vectors for high-level transgene expression in T lymphocytes | Q42798318 | ||
| Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis | Q42802250 | ||
| Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. | Q42810702 | ||
| Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease | Q43936463 | ||
| The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region | Q44081032 | ||
| Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. | Q44657197 | ||
| Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection | Q44766035 | ||
| Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays | Q45412384 | ||
| Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma | Q45640598 | ||
| Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions | Q45723253 | ||
| Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection | Q45735795 | ||
| Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. | Q45754081 | ||
| Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease | Q45756934 | ||
| Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis | Q45760941 | ||
| Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease | Q45766630 | ||
| Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. | Q45784236 | ||
| Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression | Q45785307 | ||
| Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T' cell type | Q45853463 | ||
| Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease | Q60632741 | ||
| A monoclonal antibody to the HLA-DR product recognizes a polymorphic Ia determinant in mice | Q72638934 | ||
| Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy | Q73271294 | ||
| Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma | Q75200328 | ||
| Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma | Q82107025 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| Epstein–Barr virus | Q6900 | ||
| P304 | page(s) | 3695-3704 | |
| P577 | publication date | 2010-07-29 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy | |
| P478 | volume | 116 |
| Q90778027 | A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy |
| Q35121627 | A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer |
| Q35232848 | Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations |
| Q92493499 | Detection of Epstein-Barr Virus Infection in Non-Small Cell Lung Cancer |
| Q47117102 | EBV and Apoptosis: The Viral Master Regulator of Cell Fate? |
| Q40441016 | EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas |
| Q59351745 | EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation |
| Q39284101 | Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). |
| Q37828067 | Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality? |
| Q56930876 | Epstein-Barr virus-associated lymphomas |
| Q38043974 | Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. |
| Q34898306 | Extranodal NK/T-cell lymphoma: toward the identification of clinical molecular targets |
| Q92801388 | Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type |
| Q37845178 | Immunotherapy for EBV-associated malignancies. |
| Q64065049 | Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus) |
| Q36517477 | LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL). |
| Q38597241 | Latent Membrane Protein 2 (LMP2). |
| Q38953504 | Manipulation of the host cell membrane by human γ-herpesviruses EBV and KSHV for pathogenesis |
| Q64087879 | Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL) |
| Q59382383 | Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients |
| Q40244269 | Primary NK/T cell lymphoma nasal type of the colon |
| Q44977157 | Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL). |
| Q34217852 | Sequence variations of latent membrane protein 2A in Epstein-Barr virus-associated gastric carcinomas from Guangzhou, southern China |
| Q35068768 | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins |
| Q38597252 | T-Cell Responses to EBV. |
| Q36245171 | T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice. |
| Q37948940 | T-cell therapies for Epstein-Barr virus-associated lymphomas |
| Q30278553 | The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment |
| Q92860015 | The Global Landscape of EBV-Associated Tumors |
| Q92675485 | What we should know about natural killer/T-cell lymphomas |
Search more.